Parexel Early Phase Unit at Glendale — Glendale, California

Parexel Early Phase Unit at Glendale is a clinical research site located in Glendale, California, United States 91206-4140.

Crixeo Health Trust Score: 69/100 (FAIR). This profile has not yet been claimed by the site owner.

Parexel Early Phase Unit at Glendale has participated in 12 clinical trials.

Therapeutic areas: Alzheimer's Disease, Healthy, Skin Diseases.

Sponsors: Eli Lilly and Company.

Sponsor Feasibility Report

Trust Score: 69/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Parexel Early Phase Unit at Glendale?

Parexel Early Phase Unit at Glendale has a Crixeo Trust Score of 69/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Parexel Early Phase Unit at Glendale conducted?

Parexel Early Phase Unit at Glendale has 12 clinical trials on record. Their work covers Alzheimer's Disease, Healthy, Skin Diseases.

Is Parexel Early Phase Unit at Glendale accredited by Crixeo Health?

Parexel Early Phase Unit at Glendale has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Parexel Early Phase Unit at Glendale?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.